Corbus Pharmaceuticals Holdings (CRBP) 2025 Conference June 04, 2025 04:55 PM ET Speaker0 I take analyst in Maury Raycroft's team at Jefferies. I'm happy to introduce Yuval Cohen, CEO of Corbus. He's a fireside chat firm, so thank you for joining us today, Yuval. Speaker1 Thank you for having us here. Speaker0 So for those who may be new to the story, can you provide a one minute intro to Corbus? Sure. Speaker1 We are a drug discovery company or a direct development company. We're based just South Of Boston ...

The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk (NVO) and Eli Lilly (LLY) , respectively. This space is growing at an exponential pace and is expected to reach $100 billion by 2030.The soaring demand for weight-loss drugs has pushed companies to innovate beyond GLP-1s. One emerging area of interest is cannabinoid (CBD)-based therapies, which may unlock new mechanisms for managing weight and metaboli ...

NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held June 3-5, 2025 in New York, NY. Jefferies Global Healthcare ConferenceFormat: Presentation and one-on-one investor meetingsPresentation Date: June 4, 2025Presentation ...

纪要涉及的行业和公司 - 行业：生物医药行业 - 公司：Corbus Pharmaceuticals Holdings (CRBP) 纪要提到的核心观点和论据 CRB - 701药物 - **数据情况**：西方（美英）数据与中国数据相似，安全性可比，膀胱和宫颈癌疗效相当；西方使用眼部预防措施，眼部事件明显少于中国；发现头颈部肿瘤新数据，虽患者少但结果不错，PADCEV单药治疗头颈部肿瘤ORR约20%多，CRB - 701有7例患者数据表现良好 [5][6] - **与PADCEV对比优势**：皮肤和外周神经病变不良事件显著减少，3级不良事件和停药率大幅降低，安全性更好，膀胱疗效与PADCEV相当 [8] - **开发策略**：不追求膀胱癌标签，进入PADCEV未涉及的肿瘤类型领域 [9][10] - **后续数据计划**：今年晚些时候大型肿瘤会议将公布膀胱、头颈部和宫颈癌三种肿瘤类型数据，后两者患者数量将显著增加 [13][14] - **头颈部适应症情况**：ASCO GU数据显示HPV和PD - 1均为无关因素；该领域不与PADCEV竞争，主要对比Meris和Vicara；治疗可能需与检查点抑制剂联合，决策将基于数据 [17][18][22] - **检查点抑制剂联合策略**：项目初期无法要求患者未使用过Keytruda；商业化策略取决于数据，避免重蹈Bicycle过早押注一线治疗的覆辙 [24][25][27] - **中国数据情况**：中国研究进展领先，中国药企倾向大而成熟数据集用于大会报告，具体数据公布时间待定 [29][30][33] CRB - 913药物 - **竞争优势**：Novo数据为其创造竞争壁垒，CRB - 913在大脑中的含量比Novo药物低15倍，外周限制更强 [41][42] - **研究设计**：SAD和MAD研究在健康志愿者中进行，均在美国站点，所有受试者进行神经心理评估；期望与安慰剂无差异，若MAD阶段数据干净是积极信号 [44][47][48] - **后续计划**：MAD后进行90天肥胖患者研究，数据将通过新闻稿和电话会议公布 [48][50] - **作用机制思考**：认为药物在大脑中需有一定参与度，虽在大脑与血浆比例低，但与其他药物在Dio小鼠中效果相当 [53][54] CRB - 601药物 - **差异化情况**：与Pfizer药物差异小，均靶向αvβ8以阻止潜伏TGF - β激活；Roche和AbbVie药物直接靶向潜伏TGF - β [57][58][59] - **数据计划**：今年下半年在大型医学肿瘤会议公布数据，研究包括单药治疗和与检查点抑制剂联合治疗阶段，期望单药治疗有效果 [57][59][60] 其他重要但可能被忽略的内容 - 头颈部肿瘤在美国有7.5 - 8万患者，约一半会转移；宫颈癌在美国和欧洲每年各约1.5万女性患病，约三分之一会转移，TIVDAC二线单药治疗吸引力低 [35][36] - 所有三款药物的相关数据读出都在今年下半年 [61]

Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2025 RBC Capital Markets Global Healthcare Conference, to be held May 20-21, 2025 in New York, NY. 2025 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: May 21, 2025Time: ...

Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) or Delaware 46-4348039 (State or other jurisdiction of incorporation or organization) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Norwood, MA, May 6, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2025. "During the first quarter of 2025, we continued to advance our pipeline by presenting encouraging CRB-701 Phase 1 solid tumor data from U.S. and U.K. sites at ASCO GU and initiating the CRB-913 Phase 1 study in obesity," ...

Corbus Pharmaceuticals (CRBP) closed the last trading session at $6.03, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $52.11 indicates a 764.2% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $12.31. While the lowest estimate of $35 indicates a 480.4% increase from the current price level, the most optimistic an ...

CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, announced today the dosing of the ...

文章核心观点 - 科布斯制药公司（CRBP）近期股价呈下降趋势，但因处于超卖区域且华尔街分析师认为其盈利将改善，有望趋势反转 [1] 超卖股票识别方法 - 使用相对强弱指数（RSI）识别股票是否超卖，它是衡量价格变动速度和变化的动量振荡器 [2] - RSI在0到100之间波动，通常RSI读数低于30时股票被视为超卖 [2] - RSI可帮助快速检查股票价格是否达到反转点，若因不合理抛售使股价远低于公允价值，投资者可寻找入场机会 [3] - RSI有局限性，不应单独用于投资决策 [4] CRBP可能反转的原因 - CRBP的RSI读数为26.65，表明大量抛售可能已接近尾声，股价趋势可能很快反转以恢复供需平衡 [5] - 基本面方面，覆盖该股票的卖方分析师对上调本年度盈利预测达成强烈共识，过去30天CRBP的共识每股收益（EPS）预测提高了12.9%，盈利预测上调通常会在短期内推动股价上涨 [6] - CRBP目前的Zacks排名为2（买入），意味着它在基于盈利预测修正趋势和每股收益意外情况排名的4000多只股票中处于前20%，这更有力地表明其股价短期内可能反转 [7]